Cargando…

CCI-779 (Temsirolimus) exhibits increased anti-tumor activity in low EGFR expressing HNSCC cell lines and is effective in cells with acquired resistance to cisplatin or cetuximab

BACKGROUND: The mammalian target of rapamycin (mTOR) signaling pathway plays a pivotal role in numerous cellular processes involving growth, proliferation and survival. The purpose of this study was to investigate the anti-tumoral effect of the mTOR inhibitor (mTORi) CCI-779 in HNSCC cell lines and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niehr, Franziska, Weichert, Wilko, Stenzinger, Albrecht, Budach, Volker, Tinhofer, Ingeborg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4389307/ https://www.ncbi.nlm.nih.gov/pubmed/25890004 http://dx.doi.org/10.1186/s12967-015-0456-6

Ejemplares similares

Next-generation sequencing: hype and hope for development of personalized radiation therapy?
por: Tinhofer, Ingeborg, et al.
Publicado: (2015)

Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779
por: Messina, Michael P, et al.
Publicado: (2007)

Increased Growth-Inhibitory and Cytotoxic Activity of Arsenic Trioxide in Head and Neck Carcinoma Cells with Functional p53 Deficiency and Resistance to EGFR Blockade
por: Boyko-Fabian, Mariya, et al.
Publicado: (2014)

The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells
por: Li, Shuyu, et al.
Publicado: (2013)

The Rapalogue, CCI-779, Improves Salivary Gland Function following Radiation
por: Morgan-Bathke, Maria, et al.
Publicado: (2014)

Spheroid Culture of Head and Neck Cancer Cells Reveals an Important Role of EGFR Signalling in Anchorage Independent Survival
por: Braunholz, Diana, et al.
Publicado: (2016)

Adaptive ERK signalling activation in response to therapy and in silico prognostic evaluation of EGFR-MAPK in HNSCC
por: Rong, Chao, et al.
Publicado: (2020)

Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus
por: Liu, Xiaochun, et al.
Publicado: (2016)

Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma
por: Pitter, Kenneth L., et al.
Publicado: (2011)

Correction: Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma
por: Pitter, Kenneth L., et al.
Publicado: (2011)

Survival, recurrence and toxicity of HNSCC in comparison of a radiotherapy combination with cisplatin versus cetuximab: a meta-analysis
por: Huang, Jingwen, et al.
Publicado: (2016)

阿帕替尼联合CCI-779体外抑制小细胞肺癌细胞株NCI-H446的增殖和迁移
Publicado: (2020)

Predictors for Adherence to Treatment Strategies in Elderly HNSCC Patients
por: Graessle, Raphaela, et al.
Publicado: (2022)

Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus
por: Boni, J P, et al.
Publicado: (2008)

Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer
por: Klinghammer, Konrad, et al.
Publicado: (2020)

Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines
por: Kneissl, Julia, et al.
Publicado: (2016)

The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer
por: Tinhofer, Ingeborg, et al.
Publicado: (2016)

RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximab
por: Jensen, Alexandra D, et al.
Publicado: (2010)

Interleukin 6 is increased in preclinical HNSCC models of acquired cetuximab resistance, but is not required for maintenance of resistance
por: O’Keefe, Rachel A., et al.
Publicado: (2020)

779. Clostridiodes difficile: Is it time for surveillance! Cost-benefit analysis
por: Yassin, Mohamed, et al.
Publicado: (2020)

Hepatitis B Virus Reactivation Following Treatment of HNSCC With Cisplatin
por: Crosby, James, et al.
Publicado: (2022)

Evaluating the activity of temsirolimus in neuroendocrine cancer
por: O'Donnell, P H, et al.
Publicado: (2007)

Exam ref 70-779 analyzing and visualizing data with Microsoft Excel
por: Sorensen, Chris
Publicado: (2018)

779 Utilization of Palliative Care in Patients Succumbing to Primary Burn Injury
por: Savetamal, Alisa, et al.
Publicado: (2023)

Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines
por: Busch, Chia-Jung, et al.
Publicado: (2016)

Interplay between Partial EMT and Cisplatin Resistance as the Drivers for Recurrence in HNSCC
por: Ingruber, Julia, et al.
Publicado: (2022)

Reply: Evaluating the activity of temsirolimus in neuroendocrine cancer
por: Duran, I, et al.
Publicado: (2007)

Addition of Bevacizumab to Temsirolimus in Kidney Cancer Patients
por: Boyle, H., et al.
Publicado: (2011)

A pilot study of temsirolimus and body composition
por: Veasey-Rodrigues, Heloisa, et al.
Publicado: (2013)

Hypoxia Mediates Differential Response to Anti-EGFR Therapy in HNSCC Cells
por: Wiechec, Emilia, et al.
Publicado: (2017)

779. COVID-19 Pandemic and Catheter-associated Urinary Tract Infection Trends
por: Suleyman, Geehan, et al.
Publicado: (2021)

Cetuximab and Cisplatin Show Different Combination Effect in Nasopharyngeal Carcinoma Cells Lines via Inactivation of EGFR/AKT Signaling Pathway
por: Gu, Jiajia, et al.
Publicado: (2016)

Working arrangements of the CCI computer exploitation section:
por: Madsen, Jan H B, et al.
Publicado: (1974)

Radiosensitization of HNSCC cells by EGFR inhibition depends on the induction of cell cycle arrests
por: Kriegs, Malte, et al.
Publicado: (2016)

AKT can modulate the in vitro response of HNSCC cells to irreversible EGFR inhibitors
por: Silva-Oliveira, Renato José, et al.
Publicado: (2017)

Overcoming resistance to EGFR monotherapy in HNSCC by identification and inhibition of individualized cancer processes
por: Jubran, Maria R., et al.
Publicado: (2022)

miR‐9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC
por: Citron, Francesca, et al.
Publicado: (2021)

Temsirolimus in the treatment of relapsed or refractory mantle cell lymphoma
por: Samad, Nousheen, et al.
Publicado: (2010)

Profile of temsirolimus in the treatment of advanced renal cell carcinoma
por: Staehler, Michael, et al.
Publicado: (2010)

Renal Cell Carcinoma: Focus on Safety and Efficacy of Temsirolimus
por: Hadoux, Julien, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_j9rakodij3u183lib469d7igkb